PTPN2 and PTPN1 (TC-PTP and PTP-1B)

Tyrosine-protein phosphatase non-receptor type 2 (PTPN2) and tyrosine-protein phosphatase non-receptor type 1 (PTPN1) are intracellular enzymes that regulate numerous immune and metabolic signaling pathways by removing phosphate groups from tyrosine residues on target proteins. PTPN2, also known as TC-PTP, functions as a central checkpoint for inflammation and immune tolerance, acting primarily by dephosphorylating members of the JAK and STAT families, as well as antigen receptor-associated kinases. PTPN1 (PTP-1B) predominantly regulates insulin receptor signaling and is a validated target for metabolic disease. Both enzymes have overlapping roles in dampening inflammatory and proliferative signaling, and loss or inhibition of either can heighten anti-tumor immunity but increase risk for autoimmunity and systemic inflammation. Pharmacological inhibitors, such as ABBV-CLS-484, are being evaluated for oncology, and PTPN1 inhibitors have long been explored in diabetes. Variants or altered expression levels of these phosphatases are notable biomarkers in autoimmune diseases, cancer, and metabolic disorders[1][3][7][6][4].

Other names

TC-PTPT-cell protein-tyrosine phosphatasePTP-1B

Inhibitors block enzyme activity, leading to enhanced cytokine signaling, increased immune cell activity, greater tumor cell killing, and improved insulin sensitivity